Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer.

Tanaka S, Nagase S, Kaiho-Sakuma M, Nagai T, Kurosawa H, Toyoshima M, Tokunaga H, Otsuki T, Utsunomiya H, Takano T, Niikura H, Ito K, Yaegashi N.

Int J Clin Oncol. 2014 Feb;19(1):133-8. doi: 10.1007/s10147-013-0534-9. Epub 2013 Feb 13.

PMID:
23404487
2.

Indications for primary and secondary exenterations in patients with cervical cancer.

Marnitz S, Köhler C, Müller M, Behrens K, Hasenbein K, Schneider A.

Gynecol Oncol. 2006 Dec;103(3):1023-30. Epub 2006 Aug 4.

PMID:
16890276
3.

Total pelvic exenteration for primary and recurrent malignancies.

Ferenschild FT, Vermaas M, Verhoef C, Ansink AC, Kirkels WJ, Eggermont AM, de Wilt JH.

World J Surg. 2009 Jul;33(7):1502-8. doi: 10.1007/s00268-009-0066-7.

4.

Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer.

Schmidt AM, Imesch P, Fink D, Egger H.

Gynecol Oncol. 2012 Jun;125(3):604-9. doi: 10.1016/j.ygyno.2012.03.001. Epub 2012 Mar 7.

PMID:
22406639
5.

Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: single institution experience.

Landoni F, Zanagnolo V, Rosenberg PG, Lopes A, Radice D, Bocciolone L, Aletti G, Parma G, Colombo N, Maggioni A.

Gynecol Oncol. 2013 Jul;130(1):69-74. doi: 10.1016/j.ygyno.2013.02.038. Epub 2013 Mar 6.

PMID:
23474343
6.

Survival after curative pelvic exenteration for primary or recurrent cervical cancer: a retrospective multicentric study of 167 patients.

Chiantera V, Rossi M, De Iaco P, Koehler C, Marnitz S, Ferrandina G, Legge F, Parazzini F, Scambia G, Schneider A, Vercellino GF.

Int J Gynecol Cancer. 2014 Jun;24(5):916-22. doi: 10.1097/IGC.0b013e3182a80aec.

PMID:
24442006
7.

Pelvic exenteration for recurrent or persistent cervical cancer: experience of five years at the National Cancer Institute in Mexico.

Terán-Porcayo MA, Zeichner-Gancz I, del-Castillo RA, Beltrán-Ortega A, Solorza-Luna G.

Med Oncol. 2006;23(2):219-23.

PMID:
16720922
8.

Long-term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies.

Fotopoulou C, Neumann U, Kraetschell R, Schefold JC, Weidemann H, Lichtenegger W, Sehouli J.

J Surg Oncol. 2010 May 1;101(6):507-12. doi: 10.1002/jso.21518.

PMID:
20401918
9.

Prognostic factors for curative pelvic exenterations in patients with recurrent uterine cervical or vaginal cancer.

Sardain H, Lavoué V, Laviolle B, Henno S, Foucher F, Levêque J.

Int J Gynecol Cancer. 2014 Nov;24(9):1679-85. doi: 10.1097/IGC.0000000000000288.

PMID:
25254565
10.

[Current status and outcomes of pelvic exenteration for recurrent cervical cancer: a systematic review].

Chen M, Pan L.

Zhonghua Fu Chan Ke Za Zhi. 2014 Jun;49(6):460-5. Review. Chinese.

PMID:
25169641
11.

Extended pelvic resections for recurrent uterine and cervical cancer: out-of-the-box surgery.

Caceres A, Mourton SM, Bochner BH, Gerst SR, Liu L, Alektiar KM, Kardos SV, Barakat RR, Boland PJ, Chi DS.

Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1139-44. Epub 2007 Dec 5.

PMID:
18053063
12.

Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix.

Shingleton HM, Soong SJ, Gelder MS, Hatch KD, Baker VV, Austin JM Jr.

Obstet Gynecol. 1989 Jun;73(6):1027-34.

PMID:
2726106
13.

Pelvic exenteration for adenocarcinoma of the uterine cervix.

Crozier M, Morris M, Levenback C, Lucas KR, Atkinson EN, Wharton JT.

Gynecol Oncol. 1995 Jul;58(1):74-8.

PMID:
7789894
14.

[Robot-assisted laparoscopy in the management of recurrent pelvic cancer].

Jauffret C, Lambaudie E, Bannier M, Buttarelli M, Houvenaeghel G.

Gynecol Obstet Fertil. 2011 Dec;39(12):674-80. doi: 10.1016/j.gyobfe.2011.07.021. Epub 2011 Aug 26. French.

PMID:
21871833
15.

Pelvic exenteration for recurrent squamous cell carcinoma of the pelvic organs arising from the cloaca--a single institution's experience over 16 years.

Tan KK, Pal S, Lee PJ, Rodwell L, Solomon MJ.

Colorectal Dis. 2013;15(10):1227-31. doi: 10.1111/codi.12306.

PMID:
23714581
16.
17.

Sacral resection with pelvic exenteration for advanced primary and recurrent pelvic cancer: a single-institution experience of 100 sacrectomies.

Milne T, Solomon MJ, Lee P, Young JM, Stalley P, Harrison JD, Austin KK.

Dis Colon Rectum. 2014 Oct;57(10):1153-61. doi: 10.1097/DCR.0000000000000196.

PMID:
25203370
18.

Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer.

Lopez-Graniel C, Dolores R, Cetina L, Gonzalez A, Cantu D, Chanona J, Uribe J, Candelaria M, Brom R, de la Garza J, Duenas-Gonzalez A.

BMC Cancer. 2005 Sep 19;5:118.

19.

Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: an update on out of the box surgery.

Andikyan V, Khoury-Collado F, Sonoda Y, Gerst SR, Alektiar KM, Sandhu JS, Bochner BH, Barakat RR, Boland PJ, Chi DS.

Gynecol Oncol. 2012 May;125(2):404-8. doi: 10.1016/j.ygyno.2012.01.031. Epub 2012 Jan 28.

PMID:
22285844
20.

Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma.

Gannon CJ, Zager JS, Chang GJ, Feig BW, Wood CG, Skibber JM, Rodriguez-Bigas MA.

Ann Surg Oncol. 2007 Jun;14(6):1870-7. Epub 2007 Apr 4.

PMID:
17406945

Supplemental Content

Support Center